SCHEMBL10165786

SCHEMBL10165786

CN(C)c1ccc(CNS(=O)(=O)c2ccc(Nc3ccc(-c4ccc5c(c4)CNCO5)n4ccnc34)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
TP53 P04637 2/20 0.38
NAMPT P43490 3/20 0.37
GFER P55789 1/20 0.35
LMNA P02545 2/20 0.35
AURKA O14965 1/20 0.34
FYN P06241 1/20 0.34
KMT2A Q03164 1/20 0.33
GAA P10253 4/20 0.33
THRB P10828 2/20 0.33
PKM P14618 1/20 0.33
MAPKAPK5 Q8IW41 1/20 0.33
CDK1 P06493 1/20 0.32
CDK4 P11802 1/20 0.32
CDK2 P24941 1/20 0.32
CNR1 P21554 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10166029 0.86 MAPT (0.40) MAPTTP53NAMPTKDM4ESMN1; SMN2
SCHEMBL1685229 0.85 MAPKAPK5 (0.44) MAPTTP53NAMPTGFERLMNA
SCHEMBL10165787 0.79 FYN (0.37) LMNAFYNMAPKAPK5CDK1CDK4
SCHEMBL10166838 0.76 FYN (0.45) AURKAFYN
SCHEMBL10166840 0.75 FYN (0.46) NAMPTFYNKDM4E
SCHEMBL10166846 0.75 MAPKAPK5 (0.33) FYNMAPKAPK5NPC1RAB9A
SCHEMBL10166154 0.75 NAMPT (0.39) NAMPTMAPKAPK5RAB9A
SCHEMBL10166155 0.74 TTK (0.35) NAMPTFYNMAPKAPK5
SCHEMBL10166358 0.73 BRAF (0.38) TP53NAMPTAURKAMAPKAPK5NPC1
SCHEMBL10166148 0.73 POLB (0.40) MAPTNAMPTFYNKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 MAPT 1954/4885TP53 1330/4885NAMPT 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.